Medicus Pharma Secures $1B+ Global License from Pfizer for CD228V ADC
MDCX is trading near its 52-week low of $0.151 (12% above the low) on elevated volume (30× avg).
Summary
Medicus Pharma signed an exclusive global license with Pfizer for PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin. The deal requires $12M upfront and $15M on the first anniversary, with Pfizer providing $2M in development funding. Pfizer stands to receive over $1B in milestone payments plus low double-digit royalties. Medicus retains sole authority for manufacturing, regulatory, and commercialization. This follows the 8-K filed earlier today disclosing the co-development deal; the news adds specific financial terms and notes the stock fell 32% to $0.18 on Thursday. The agreement is highly significant for a company with a market cap around $10M and cash of $15.2M, as it brings a major pharma partner and potential future revenue, though the upfront payments are substantial relative to its resources. Watch for further details on development timelines and any financing to cover the $27M in payments.
At the time of this announcement, MDCX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.15 to $3.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.